How does the blend try to work?

Through four independent mechanisms: L-Carnitine shuttles fatty acids into the mitochondria for beta-oxidation (CPT-I shuttle, injectable to bypass poor oral absorption); the MIC trio (Methionine, Inositol, Choline) supports hepatic fat metabolism and fat export (methyl donors); ATP and B12 are energy and methyl-metabolism cofactors; and albuterol, as a selective beta-2 agonist, adds a mild thermogenic / lipolytic effect. IMPORTANT: the clinical fat-loss evidence is for the INDIVIDUAL components (and even there it is modest), not for this specific combination.

Why is it WADA-banned?

Albuterol (Salbutamol) is a selective beta-2 adrenergic agonist. WADA permits inhaled use up to <1600 µg/24h (in an asthma context), but ORAL and INJECTABLE beta-2 agonist use is BANNED. Because Super-Shred is injectable and contains albuterol, the whole blend is prohibited in competition (urine detection 24-72 h, threshold 1000 ng/mL).

The lipotropic components (choline, methionine, inositol) and the cofactors (ATP, B12) support hepatic fat metabolism on their own and are not hepatotoxic. The real risk comes from the albuterol component: tachycardia, tremor, hypokalaemia and cardiovascular strain. On top of that is the uncertainty of grey-market / home formulation – purity, sterility and actual dose are NOT guaranteed. It is contraindicated with pre-existing cardiovascular disease, hyperthyroidism, a MAO inhibitor or a beta-blocker.

EmergingResearch compound

Super‑Shred (lipotropic blend)

Name: Super-Shred (lipotropic blend)
Creator: MolekulaX

Compounded INJECTABLE lipotropic fat-burner cocktail (the classic 'lipo shot' archetype): L-Carnitine 400 mg + MIC blend 100 mg (Methionine + Inositol + Choline) + ATP 50 mg + Albuterol 2 mg + B12 1 mg. Fatty-acid transport (carnitine) + hepatic lipotropics (MIC) + a beta-2 thermogenic (albuterol) + cofactors (ATP, B12) in one injection. WADA-banned because of the albuterol, and it carries real cardiovascular risk. The clinical fat-loss evidence is for the individual components, NOT for the blend.

WHAT IS SUPER-SHRED (LIPOTROPIC BLEND)?

Detailed overview

'Super-Shred (lipotropic blend)' is a compounded, INJECTABLE fat-burner cocktail – a specific version of the classic 'lipo shot' / lipotropic-injection archetype. It combines five components in one aqueous injection: L-Carnitine 400 mg (long-chain fatty-acid shuttle), MIC blend 100 mg (Methionine + Inositol + Choline lipotropic trio), ATP 50 mg (energy/substrate), Albuterol 2 mg (selective beta-2 agonist) and B12 / cyanocobalamin 1 mg (energy and methyl-metabolism cofactor). The logic is four-layered: fatty-acid transport (carnitine) + hepatic lipotropics (MIC) + beta-2 thermogenic lipolysis (albuterol) + cofactors (ATP, B12). The injectable route bypasses the poor oral bioavailability of carnitine (~15%). IMPORTANT honest framing: the clinical fat-loss evidence is overwhelmingly for the INDIVIDUAL components (and even there it is modest), NOT for this specific blend – there is no RCT of this combination. The real risk comes from the albuterol component: tachycardia, tremor, hypokalaemia and cardiovascular strain, and it is a WADA-banned beta-2 agonist. The preparation is grey-market, compounded / home-mixed, so purity and actual active content are NOT guaranteed.

Type

Compounded injectable lipotropic fat-burner cocktail (5-component 'lipo shot')

Composition

L-Carnitine 400 mg + MIC 100 mg + ATP 50 mg + Albuterol 2 mg + B12 1 mg per injection

Mechanism

Fatty-acid shuttle (carnitine) + hepatic lipotropics (MIC) + beta-2 thermogenic (albuterol) + cofactors (ATP, B12)

Administration

Subcutaneous / intramuscular injection (aqueous solution)

Legal status

No approved fixed-dose blend exists; compounded / grey-market. Albuterol beta-2 agonist is WADA-banned (oral/injectable). EU + HU: Rx components.

Composition

This stack contains the following peptides

MIC Blend (Methionine, Inositol, Choline)

Role: Lipotropic trio (Methionine + Inositol + Choline) – supports hepatic lipid metabolism and fat export; choline + methionine are methyl donors

100 mg

ATP

Role: Cellular energy / substrate component

50 mg

B12 (cyanocobalamin)

Role: Cyanocobalamin – cofactor in energy and methyl metabolism, added for energy support

1 mg

Data console

Lab data

/lab/molecular-data.jsonLIVE
> Androgenic:AnabolicN/A (not AAS)
> AR bindingN/A
> Active half-lifeComponent-dependent: albuterol ~5-6 h, L-carnitine ~15 h, B12 is stored
> Detection windowAlbuterol 24-72 h urine (WADA threshold 1000 ng/mL). L-Carnitine is not a standard WADA test; B12 / lipotropics are not listed.
> AromatizationDoes not aromatize – not a steroid. The blend consists of lipotropics, a beta-2 agonist and cofactors, with no CYP19 (aromatase) interaction and no estrogen-axis effect.
> HepatotoxicityThe lipotropic components (choline, methionine, inositol) generally SUPPORT hepatic fat metabolism and fat export, so they are not hepatotoxic on their own. Honest note: because Super-Shred is a compounded / grey-market injectable, purity, sterile manufacturing and actual active content are NOT guaranteed – here the risk comes not from hepatotoxicity but from the purity and sterility uncertainty of home formulation and from the cardiovascular effect of the albuterol.

Safety

Side effects, stop signs, contraindications

Side effects · 8

Tachycardia and palpitations: the Albuterol beta-2 agonist effect raises heart rate and causes palpitations, especially at higher doses or combined with other stimulants.
Hand tremor (fine shaking): beta-2 receptor stimulation causes a characteristic, dose-dependent skeletal-muscle tremor, most often in the hands.
Hypokalaemia (low blood potassium): beta-2 activation shifts potassium into cells, which can cause muscle weakness and arrhythmia risk, especially alongside diuretics.
Restlessness, anxiety, insomnia: the sympathomimetic effect of Albuterol can cause nervousness, inner tension and disturbed sleep.
Headache and muscle cramps: a common beta-2 agonist side effect; the cramping can be aggravated in part by hypokalaemia.
Injection-site reaction and sterility risk: with grey-market/compounded aqueous injectables purity and sterility are not guaranteed, so local pain, inflammation, abscess or infection can occur.
Dose uncertainty (compounded mix): the actual Albuterol content can deviate significantly from the labelled amount, causing unpredictable cardiovascular load.
L-Carnitine TMAO elevation: chronic carnitine intake can be converted by gut microbiota to TMAO, which has been linked over the long term to atherosclerosis risk (Koeth 2013).

Contraindications · 7

Pre-existing tachyarrhythmia, atrial fibrillation or cardiomyopathy: the Albuterol beta-2 effect worsens the arrhythmia, an absolute contraindication.
Untreated or severe hypertension (>140/90 mmHg): the sympathomimetic load further raises blood pressure.
Hyperthyroidism / Graves disease: contraindicated due to heightened adrenergic sensitivity and arrhythmia risk.
Pregnancy and breastfeeding: the beta-2 agonist crosses over and has tocolytic/cardiovascular effects; the compounded mix has no established safety.
Concurrent beta-blocker or MAO-inhibitor therapy: a beta-blocker blocks the effect and may cause vasoconstriction, while with an MAO inhibitor there is a risk of hypertensive crisis and tachycardia.
Combination with another beta-2 agonist/stimulant (clenbuterol, ECA stack, caffeine): additive cardiac stress and hypokalaemia, contraindicated.
WADA-tested athletes: injectable/oral Albuterol beta-2 agonist use is prohibited in competition (only inhaled <1600 ug/24h is permitted).

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

J Physiol. 2007;581(Pt 2):431-444.

New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle

Stephens FB, Constantin-Teodosiu D, Greenhaff PL.

PMID: 17331998Open

Nat Med. 2013;19(5):576-585.

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

Koeth RA, Wang Z, Levison BS et al.

PMID: 23563705Open

Pharmacol Rev. 2012;64(3):450-504.

Pharmacology and therapeutics of bronchodilators

Cazzola M, Page CP, Calzetta L, Matera MG.

PMID: 22611179Open

J Strength Cond Res. 2003;17(3):455-462.

L-carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress

Kraemer WJ, Volek JS, French DN et al.

PMID: 12930169Open

Have a question about Super‑Shred (lipotropic blend)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: June 19, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.